Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Glucophage XR Reduced Mass vs Marketed Glucophage XR in Healthy Participants
NCT04684420Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Dec 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration and Maximum Observed Plasma Concentration. Started Dec 2020; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04684420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04684420.